KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Net Income towards Common Stockholders: 2019-2024

Historic Net Income towards Common Stockholders for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Dec 2024 value amounting to -$463.7 million.

  • Recursion Pharmaceuticals' Net Income towards Common Stockholders fell 69.29% to -$162.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$715.5 million, marking a year-over-year decrease of 89.42%. This contributed to the annual value of -$463.7 million for FY2024, which is 41.33% down from last year.
  • Recursion Pharmaceuticals' Net Income towards Common Stockholders amounted to -$463.7 million in FY2024, which was down 41.33% from -$328.1 million recorded in FY2023.
  • Recursion Pharmaceuticals' 5-year Net Income towards Common Stockholders high stood at -$84.6 million for FY2020, and its period low was -$463.7 million during FY2024.
  • Its 3-year average for Net Income towards Common Stockholders is -$343.7 million, with a median of -$328.1 million in 2023.
  • Data for Recursion Pharmaceuticals' Net Income towards Common Stockholders shows a maximum YoY plummeted of 120.39% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Recursion Pharmaceuticals' Net Income towards Common Stockholders stood at -$84.6 million in 2020, then plummeted by 120.39% to -$186.5 million in 2021, then declined by 28.42% to -$239.5 million in 2022, then plummeted by 36.99% to -$328.1 million in 2023, then plummeted by 41.33% to -$463.7 million in 2024.